Consolidated Statement Of Income

Kringle Pharma,Inc. - Filing #7264672

Concept 2024-10-01 to
2025-03-31
2023-10-01 to
2024-03-31
Consolidated statement of income
Statement of income
Net sales
35,928,000 JPY
43,029,000 JPY
Cost of sales
JPY
JPY
Operating expenses
Selling, general and administrative expenses
547,862,000 JPY
409,776,000 JPY
Operating expenses
Ordinary profit (loss)
-511,740,000 JPY
-365,471,000 JPY
Gross profit (loss)
35,928,000 JPY
43,029,000 JPY
Operating profit (loss)
-511,933,000 JPY
-366,746,000 JPY
Net sales
Operating expenses
Research and development expenses
404,978,000 JPY
293,788,000 JPY
Non-operating income
Interest income
29,000 JPY
7,000 JPY
Other
115,000 JPY
0 JPY
Non-operating income
257,000 JPY
1,275,000 JPY
Selling, general and administrative expenses
Cost of sales
Non-operating expenses
Non-operating expenses
65,000 JPY
JPY
Gross profit
Profit (loss) before income taxes
-511,740,000 JPY
-365,471,000 JPY
Income taxes - current
749,000 JPY
746,000 JPY
Income taxes
749,000 JPY
746,000 JPY
Profit (loss)
-512,490,000 JPY
-366,217,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.